(CercleFinance.com) – Novo Nordisk today announced the main results of the FLOW trial comparing injectable semaglutide 1.0 mg to placebo to prevent the progression of renal failure and the risk of renal and cardiovascular mortality in people with type 2 diabetes and chronic kidney disease (CKD).
The trial (which included 3,533 people with type 2 diabetes and CKD) met its primary endpoint by demonstrating ‘a statistically significant reduction’ in the progression of kidney disease, major adverse cardiovascular events ( MACE) and deaths of 24% in people treated with semaglutide 1.0 mg compared to placebo.
Therefore, Novo Nordisk plans to file for regulatory approval for a label expansion of Ozempic (the trade name for semaglutide) in the US and EU in 2024.
Detailed results from FLOW will be presented at a scientific conference later this year.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
